
    
      In this study, we will examine whether DCs pulsed with candidate melanoma-specific peptides
      and KLH can boost CTL responses to melanoma antigens in melanoma patients who are clinically
      free of disease but at high risk for recurrence. This vaccine will be compared to direct
      injection of the same peptides with KLH and Montanide as adjuvant.
    
  